S100A、P53对宫颈癌行顺铂新辅助化疗患者疗效及敏感性评估

Evaluation on the efficacy and sensitivity of S100A and P53 in the patients with cervical cancer undergoing cisplatin neoadjuvant chemotherapy

目的探讨S100A6、P53对宫颈癌行顺铂新辅助化疗患者的疗效及化疗敏感性评估价值。方法选取2017年1～12月我院收治的行顺铂新辅助化疗的宫颈癌患者70例,观察不同临床疗效患者的S100A6、P53表达情况。结果 70例患者中完全缓解(CR)8例,部分缓解(PR)51例,疾病稳定(SD)6例,疾病进展(PD)5例,化疗总有效率为84.29%(59/70);化疗前S100A6、P53阳性表达率为85.71%、61.43%,化疗后S100A6、P53阳性表达率为45.71%、84.29%,化疗后S100A6阳性表达率较化疗前明显降低(P<0.05),P53阳性表达率较化疗前明显升高(P<0.05);高敏感组S100A6、P53阳性表达率分别为27.12%、91.53%,低敏感组S100A6、P53阳性表达率分别为90.91%、45.45%,高敏感组S100A6阳性表达率明显低于低敏感组(P<0.05),P53阳性表达率明显高于低敏感组(P<0.05)。结论 S100A6、P53可作为宫颈癌患者行顺铂新辅助化疗效果和敏感性预测的标志物。

Objective To investigate the efficacy of S100A6 and P53 in the patients with cervical cancer receiving cisplatin neoadjuvant chemotherapy and the evaluation value of chemosensitivity. Methods 70 patients with cervical cancer who were admitted to our hospital and were given neoadjuvant chemotherapy with cisplatin from January to December 2017 were selected. The expression of S100A6 and P53 in the patients with different clinical efficacy was observed. Results Among the 70 patients, 8 patients had complete remission(CR), 51 patients had partial remission (PR), 6 patients had stable disease(SD), and 5 patients had disease progression(PD). The total effective rate of chemotherapy was 84.29%(59/70);the positive expression rate of S100A6 and P53 before chemotherapy was 85.71% and 61.43%. The positive expression rate of S100A6 and P53 after chemotherapy was 45.71% and 84.29%. The positive expression rate of S100A6 after chemotherapy was significantly lower than that before chemotherapy(P<0.05). The positive expression rate of P53 was significantly higher than that before chemotherapy(P<0.05);the positive expression rates of S100A6 and P53 in the high sensitive group were 27.12% and 91.53%, respectively. The positive expression rates of S100A6 and P53 in the low sensitivity group were 90.91% and 45.45%, respectively. The positive expression rate of S100A6 in the high sensitivity group was significantly lower than that in the low sensitivity group(P<0.05). The positive expression rate of P53 was significantly higher than that in the low sensitivity group(P<0.05). Conclusion S100A6 and P53 can be used as markers for the prediction of the efficacy and sensitivity of cisplatin neoadjuvant chemotherapy in the patients with cervical cancer.